1433281-16-3

Upstream product

• 1250939-45-7 (2S,4S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-4-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 364750-81-2 N-tert-Butyloxycarbonyl-(2S,4S)-4-methylproline 
• 1250939-42-4 (2-(2-(4-bromophenyl)-2-oxoethyl)) 1-(tert-butyl) (2S,4S)-4-methylpyrrolidine-1,2-dicarboxylate 
• 1433280-51-3 (R)-(5-chloro-4-(6-(2-methyl-4-pivaloylpiperazin-1-yl)nicotinamido)-2-(trifluoromethoxy)phenyl)boronic acid 
• 1374892-54-2 (R)-4-[5-(4-bromo-2-chloro-5-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 1374892-55-3 N-(4-bromo-2-chloro-5-trifluoromethoxy-phenyl)-6-fluoro-nicotinamide 
• 1433280-32-0 (2S,4S)-2-{4-[5'-chloro-4'-({6-[(R)-4-(2,2-dimethyl-propionyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-2'-trifluoromethoxy-biphenyl-4-yl]-1H-imidazol-2-yl}-4-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1307310-41-3 (2S,4S)-4-methyl-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1433280-30-8 N-(4-bromo-2-chloro-5-trifluoromethoxy-phenyl)-6-[(R)-4-(2,2-dimethyl-propionyl)-2-methyl-piperazin-1-yl]-nicotinamide 
• 115844-00-3 4-bromo-2-chloro-5-(trifluoromethoxy)phenylamine 
• 116369-25-6 4-bromo-3-(trifluoromethoxy)phenylamine 

Relevant academic research and scientific papers

CRYSTALLINE FORM OF A HEPATITIS C VIRUS INHIBITOR

The invention provides the crystalline hydrate of [(S)-2-((2S,4S)-2-{4-[5'-chloro-4'-({6-[(R)-4-(2,2-dimethyl-propionyl)-2-methyl-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-2'-trifluoromethoxy-biphenyl-4-yl]-1H-imidazol-2-yl}-4-methoxy-pyrrolidin-1-yl)-2-oxo-1-(tetrahydro-pyran-4-yl)-ethyl]-carbamic acid methyl ester dihydrochloride The invention also provides pharmaceutical compositions comprising thecrystalline form, methods of using the crystalline form to treat hepatitis C virus infection, and processes useful for preparing the crystalline form.

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.